GlassScriptPhysician profile
Brian M Deloach
NPI 1841202868
$6,360.53
in general payments reported to CMS, 2019-2025
39 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,067 · 2023: $1,885 · 2024: $1,797 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,274 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,273.53 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $708.69 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $544.34 | 2022-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $457.50 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $401.00 | 2022-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $388.29 | 2022-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $380.27 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $313.80 | 2022-2025 | |
| Glaxosmithkline, LLC. | $281.74 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Tris Pharma INC | $270.18 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $224.99 | 2023-2025 | Rexulti |
| Dexcom, INC. | $202.85 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.83 | 2022-2025 | Xifaxan, Trulance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.57 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $192.46 | 2023-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.19 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $128.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $116.48 | 2023-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $106.68 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $101.48 | 2022-2025 | Gardasil 9, Capvaxive, Januvia |
| Novartis Pharmaceuticals Corporation | $89.48 | 2022-2024 | |
| Corium, LLC | $87.09 | 2023 | Azstarys |
| Abbott Laboratories | $84.22 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $77.24 | 2023-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $76.40 | 2022-2023 | Seglentis, Livalo |
| Teva Pharmaceuticals USA, INC. | $69.86 | 2022-2024 | Austedo Xr, Airduo Digihaler |
| Ironshore Pharmaceuticals INC. | $64.70 | 2023-2024 | Jornay Pm |
| Harmony Biosciences LLC | $63.67 | 2022-2024 | Wakix |
| Sanofi-Aventis U.S. LLC | $56.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.78 | 2022-2025 | Trintellix |
| Astellas Pharma US INC | $44.24 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $38.42 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $29.91 | 2022-2023 | Nexletol |
| Antares Pharma, INC. | $29.69 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $28.65 | 2022 | |
| Vanda Pharmaceuticals INC. | $25.94 | 2025 | Fanapt |
| Corcept Therapeutics | $23.54 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $20.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.28 | 2025 | Spravato |
| Sumitomo Pharma America, INC. | $12.18 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Deloach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.